Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
wharton's jelly-derived mesenchymal stem cells (Karolinska Institutet)
- Development stage
- Unknown
- Lead developer
- Polski Bank Komórek Macierzystych
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous, Intra-arterial, Parenteral
01
Overview
Wharton's Jelly-derived Mesenchymal Stem Cells (WJMSCs) are a population of multipotent stromal cells harvested from the mucoid connective tissue of the human umbilical cord. These cells are highly valued in regenerative medicine due to their robust proliferative capacity, low immunogenicity, and potent immunomodulatory properties. WJMSCs function primarily through paracrine mechanisms, secreting a diverse secretome that includes anti-inflammatory cytokines (such as IL-10 and TGF-beta), growth factors (like VEGF), and extracellular vesicles (exosomes). These factors promote tissue repair, stimulate angiogenesis, and modulate immune responses by inducing M2 macrophage polarization and suppressing T-cell activation. WJMSCs are currently being evaluated in clinical trials for a variety of conditions, including acute myocardial infarction, coronary artery disease, type 1 diabetes, and ischemic cardiomyopathy, as well as for applications in wound healing and skin rejuvenation.
- Other names
- Wharton's Jelly Mesenchymal Stem CellsWharton's Jelly Mesenchymal Stromal CellshWJMSCshuman umbilical cord Wharton's jelly-derived mesenchymal stem cellsWJ-MSCs
Beyond the preview
Go deeper on wharton's jelly-derived mesenchymal stem cells (Karolinska Institutet).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on wharton's jelly-derived mesenchymal stem cells (Karolinska Institutet).